INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial

The purpose of this study was to compare intravitreal nesvacumab (anti-angiopoietin 2) plus aflibercept with intravitreal aflibercept injection (IAI) in diabetic macular edema. METHODS: The eyes (n = 302) were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + afl...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, David M., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Heier, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2022
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112959/
https://www.ncbi.nlm.nih.gov/pubmed/35234673
http://dx.doi.org/10.1097/IAE.0000000000003441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112959/
https://www.ncbi.nlm.nih.gov/pubmed/35234673
http://dx.doi.org/10.1097/IAE.0000000000003441

Ejemplares similares